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RESEARCH ARTICLE Open Access
Incidence and impact on prognosis of peri-
procedural myocardial infarction in 2760
elective patients with stable angina
pectoris in a historical prospective follow-
up study
Martin Kirk Christensen1*, Hui Huang2, Christian Torp-Pedersen3, Torleif Trydal4 and Jan Ravkilde1
Abstract
Background: The clinical significance of myocardial infarction related to treatment with percutaneous coronary
intervention (PCI) has been subject of great discussion. This subject has been studied for many years using different
definitions of peri-procedural myocardial infarction and different biomarkers, the results have varied greatly
depending on methods and time of the study. This study was to determine the incidence and prognostic
significance of elevated cardiac biomarkers after elective PCI in patients with stable angina pectoris using the
current cut-off set by the Third Universal Definition of Myocardial Infarction and current biomarkers.
Methods: We performed a historical prospective follow-up study of all patients with stable angina pectoris who
underwent elective PCI at Aalborg University Hospital, Denmark from January 1st 2000 to December 31st 2012. We
stratified patients according to peak post-PCI troponin T (cTnT) and Creatine Kinase MB mass (CK-MBmass).
Results: Follow-up for time to all-cause mortality was mean 5.8 years and total 15,891 years and mean 3.7 years
and total 10,160 years for the combined endpoint of all-cause mortality and new onset heart failure. During the
follow up period 399 of 2760 patients died (14.5 %) and 1095 (39.7 %) suffered the combined endpoint. Post-PCI
concentration of cTnT and CK-MBmass was elevated above the defined cut-off in 419 patients (15.2 %) and 113
patients (4.1 %) respectively. There was no statistically significant difference between the groups in stratified analysis
of the hazard rates by time regarding all-cause mortality for cTnT nor CK-MBmass. Regarding the combined
endpoint the results were ambiguous. The results were unchanged in multivariable analyses that included age and
gender.
Conclusion: The incidence of elevated biomarkers after elective PCI in patients with stable angina pectoris using
the defined cut-off (>5 x URL) was 15.2 % using cTnT and 4.1 % using CK-MBmass. The independent prognostic
value for both cardiac biomarkers of any cut-off showed no statistical significance for all-cause mortality, whereas
the combined endpoint (all-cause mortality or new-onset heart failure) were ambiguous in both short- and
long-term follow-up.
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Background
Percutaneous coronary intervention (PCI) is an estab-
lished procedure for the treatment of both stable angina
pectoris and acute coronary syndrome, but the procedure
is not without risk. An important complication to PCI is
myocardial infarction (MI). This form of MI has been de-
fined as MI type 4a by the Third Universal Definition of
Myocardial Infarction Task Force Group [1]. Despite the
clear definition, it remains unclear whether the chosen
cut-off for biomarker concentration post-PCI is clinically
and prognostically meaningful and should lead to changes
in the treatment strategy [2].
The biomarker historically used for this purpose has
been creatine kinase isoenzyme MB (CK-MB) initially as
a measure of activity followed by analysis of mass con-
centration. Previous studies have shown a proportional
relationship between rise in CK-MB and 6-month all-
cause mortality [3, 4]. CK-MB has been largely replaced
by high sensitive cardiac troponins T or I (cTn) as the
biomarkers of choice in all types of myocardial infarction
due to both higher sensitivity and specificity for myocar-
dial necrosis [1, 2].
The aims of this study were to determine the inci-
dence of elevated biomarkers post-PCI using the cut-off
set by the Third Universal Definition of Myocardial In-
farction in a cohort of patients with stable angina pec-
toris undergoing elective PCI and to determine the
prognostic significance of this arbitrarily set limit of car-
diac biomarker elevation defining peri-procedural MI by
evaluating primarily all-cause mortality and secondarily
a combined endpoint of all-cause mortality and heart
failure.
Methods
Study design and inclusion
We performed a historical prospective follow up study of
a cohort of patients with stable angina pectoris who
underwent elective PCI at Aalborg University Hospital,
Denmark from January 1st 2000 to December 31st 2012.
Patients were eligible if the procedure was elective and
there was no elevation of troponin prior to the procedure.
Selection of the included 2760 patients can be followed in
Fig. 1. As per department routine, patients had cTnT and
CK-MBmass measured immediately before or during the
procedure and 3–24 h later. In patients with more than
one sample post-PCI, the highest value for cTnT was in-
cluded. Patients who underwent several separate proce-
dures were only included in analysis for the first
intervention. All patients with a previous diagnosis of
heart failure were excluded from analysis of the secondary
endpoint of new-onset heart failure. As older studies have
used CK-MB and not cTn, we also analyzed peak post-
PCI CK-MBmass from the same cohort included in ana-
lysis for cTnT sampled from 3–24 h after the procedure.
Fig. 1 Study flow chart. cTnT = peak post procedural concentration of troponin T. CK-MB = peak post procedural concentration of CK-MBmass.
URL = Upper reference limit
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Biochemical analysis
cTnT and CK-MBmass were measured using a chemilu-
miniscence assay on either Elecsys 2010, Cobas 6000 or
Cobas 8000 (Roche, Mannheim, Germany). The cTnT
analysis changed to the new high sensitive version
(hsTnT) in June 2010. Alignment of the concentrations
between the cTnT and the hsTnT measurements was
done according to a comparison study and information
from the provider [5]. The 99th percentile upper refer-
ence limit (URL) of hsTnT has been determined to be
14 ng/L, and the 99th percentile of 4th generation TnT
analysis has been determined to less than 10 ng/L [5, 6].
Values up to 14 ng/l in hsTnT methods, or less than
10 ng/L in non-hsTnT methods, were defined as normal
values. We considered that different versions of the
TnT-assays had the same standardization from cTnT-
values 70 ng/L and above. The cTnT value of 70 ng/L is
also 5 x URL set by the Third Universal Definition Myo-
cardial Infarction [1].
The CK-MB was measured as massconcentration and
the assays underwent no change of standardization in
the period in question. URL for CK-MBmass is gender
specific and the current URL of 4 μg/L and 7 μg/L for
woman and men (information from the provider, [6]),
respectively, were used.
The analyses were performed as instructed by the pro-
vider. Internal quality controls at low and high concen-
trations, and external quality assessment (Labquality,
Helsinki, Finland) were performed regularly throughout
the period. The results were obtained from the clinical
laboratory information system LABKA1 and LABKA2
databases [7].
Follow-up
In this study data from one center, Aalborg University
Hospital, was included. All patients were continuously
registered in the Western Denmark Heart Registry im-
mediately after the procedure [8]. In this registry patient
data are available including risk factors, previous cardiac
disease, clinical data e.g., body weight, blood pressure,
latest P-Creatinine, indication, priority and procedural
details such as number of treated vessels and details re-
garding type and number of stents used. Using the
Western Denmark Heart Registry we were able to re-
strict our cohort to PCI performed on the indication
stable angina pectoris that were performed electively.
To link databases and follow the patients we extracted
information from the Danish National Civil Registration
System, which identifies all Danish citizens with a unique
personal identification number. Death is registered in this
system within 2 weeks of death. The data, including date
of birth, sex and date of death is updated continuously
and is considered highly valid [9]. New onset heart failure
required that the patient did not have a clinical diagnosis
of heart failure prior to the procedure and further did use
furosemide for a period of 60 days prior to the procedure.
New onset heart failure was then considered to take place
if the patient collected a prescription for furosemide or
was admitted to hospital with a diagnosis of heart failure.
Prescriptions were identified in the Danish Register of
Medicinal Product Statistics, maintained by the Danish
Medicines Agency. It contains information on all dis-
pensed prescriptions from Danish pharmacies since 1994,
including dosage, dispensing date and quantity of the drug
dispensed. All drugs are categorized according to the Ana-
tomical Therapeutic Chemical classification system [10].
Endpoints were chosen to all-cause mortality and the
combined endpoint of all-cause mortality and new onset
heart failure.
This study complies with the Declaration of Helsinki
and STROBE guidelines. According to Danish law no
specific approval from a local ethics committee or in-
formed consent from the patients was required for this
registry study. Permission was obtained to use data from
Western Denmark Heart Registry. The study was ap-
proved by the Danish Data Protection Agency.
Statistical analysis
Statistical analysis was performed in three and four groups
after peak post-PCI concentrations of cTnT, the three
groups were: ≤14 ng/L (URL), >14–70 ng/L and >70 ng/L
(5x URL) and as four groups ≤14 ng/L (URL), >14–70 ng/
L, >70–200 ng/L and >200 ng/L and four groups for CK-
MBmass: < 4 μg/L (women) or 7 μg/L (men)), 4–20 μg/L
or 7–35 μg/L; 20–60 μg/L or 35–105 μg/L and >60 μg/L
or >105 μg/L for women and men, respectively. The
values for CK-MBmass correspond to URL, 5 x URL and
15 x URL.
Comparison of baseline demographics was performed
using rank-sum tests for continuous variables and chi-
square for discrete variables. Survival curves were con-
structed from Kaplan Meier survival estimates and dif-
ferences were analyzed using Cox Proportional Hazard
Models. Analyses were performed with SAS (Statistical
Analysis System, version 9.4, The SAS Institute) and R
version 3.02 (R core development team) [11].
Results
From January 1st 2000 to December 31st 2012; 4137 elect-
ive PCIs were performed on the diagnosis of stable angina
pectoris, from this we identified 2760 patients eligible for
further analysis (Fig. 1). Seventeen additional patients
were excluded from analysis for CK-MBmass due to miss-
ing values. Follow-up for time to death was mean 5.8 years
and total 15,891 years and mean 3.7 years and total
10,160 years for the combined endpoint of all-cause mor-
tality and new onset heart failure. During the follow up
period 399 patients died (14.5 %) and 1095 (39.7 %)
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suffered the combined endpoint. The incidence of ele-
vated biomarkers post-PCI with cTnT exceeding URL was
1040/2760 (37.7 %) and 419/2760 (15.2 %) exceeding 5 x
URL. Correspondingly for CK-MBmass 643/2743 (23.4 %)
above URL and only 113/2743 (4.1 %) exceeded 5 x URL.
Table 1 shows the key elements of previous medical
history, clinical and angiographic data in the four groups
according to peak post-PCI cTnT. Of the 2760 included
patients there was a high prevalence of risk factors for
ischemic heart disease with male sex (71 %), age (mean
65 years), current smoking (25.9 %), diabetes (15.3 %),
medically treated hypertension (64.3 %), medically
treated hypercholesterolemia (70.8 %) and family history
of coronary artery disease (49.2 %). The risk factors were
evenly distributed among the groups with few statisti-
cally significant differences. The group with lowest cTnT
were statistically significantly younger (64 years versus
67 years) than the other groups. Kidney function evalu-
ated by P-Creatinine was also slightly but statistically
significantly lower in the group with lowest cTnT
(83 μmol/L versus 86 μmol/L). For severity of symptoms,
all patients were evaluated by Canadian Cardiovascular
Society classification of angina pectoris (CCS) with an
even distribution and 87.7 % with angina pectoris CCS
1-2. As expected, the patients often had previous MI
(26.6 %) and previous revascularization with PCI
(23.4 %). There were statistically significantly more pre-
vious MIs in the group with cTnT >14–70 ng/L. With
the lowest mean age in the group with cTnT ≤14 ng/L
and the highest number of stents being used in the two
groups with cTnT above 70 ng/L. Post-PCI peak values
for cTnT were mainly distributed below the defined cut-
off, but of the 2760 patients 419 (15.2 %) had elevated
cTnT above 5 x URL post-PCI.
The Kaplan-Meier curve of all-cause mortality by peak
concentration of troponin T showed no sign of separ-
ation between the curves until after approximately
6 years (2000 days). After this time point, there was a
slight tendency towards lower all-cause mortality in the
group with cTnT ≤14 ng/L, but this was not statistically
Table 1 Patient characteristics
Post-PCI peak TnT (ng/L) ≤14 (n = 1720) >14-70 (n = 621) >70-200 (n = 211) >200 (n = 208) P Value
Clinical data
Age - years (IQR) 64 (57, 71) 67 (60, 74) 67 (59, 74) 67 (59, 73) <0.0001
Male sex - no. (%) 1220 (70.9) 435 (70.0) 161 (76.3) 154 (74.0) 0.27
Angina severity CCS 1 247 (18.8) 94 (18.9) 28 (17.9) 26 (16.4)
Angina severity CCS 2 913 (69.4) 365 (73.4) 111 (71.2) 121 (76.1)
Angina severity CCS 3 151 (11.5) 36 (7.2) 17 (10.9) 11 (6.9)
Angina severity CCS 4 4 (0.3) 2 (0.4) 0 (0.0) 1 (0.6) 0.34
Body Mass Index - kg/m2 (IQR) 26.3 (23.4, 29.3) 26.6 (23.5, 30.0) 25.8 (23.1, 29.2) 27.2 (24.4, 30.5) 0.23
P-Creatinine - μmol/L median (IQR) 83 (73, 96) 84 (74, 99) 85 (74, 100) 86 (75, 101) 0.01
Risk factors
Smoking - Current - no. (%) 454 (27.2) 132 (21.8) 44 (21.2) 55 (26.8) 0.22
Non-insulin dependent diabetes- no. (%) 177 (10.5) 54 (9.1) 21 (10.3) 20 (10.0)
Insulin dependent diabetes - no. (%) 80 (4.8) 34 (5.7) 9 (4.4) 10 (4.9) 0.62
Medically treated hypertension - no. (%) 1038 (62.8) 399 (67.2) 133 (64.3) 134 (66.3) 0.19
Medically treated hypercholesterolemia - no. (%) 1166 (70.5) 428 (71.6) 145 (70.0) 138 (68.3) 0.92
Family history of coronary artery disease - no. (%) 822 (49.6) 289 (48.5) 91 (44.2) 94 (46.5) 0.13
Medical history
Previous myocardial infarction - no. (%) 439 (25.5) 184 (29.6) 59 (28.0) 51 (24.5) 0.034
Previous percutaneus coronary
intervention - no. (%)
397 (23.9) 146 (24.4) 54 (26.1) 48 (23.8) 0.93
Medically treated heart failure 135 (7.8) 66 (10.6) 21 (10.0) 26 (12.5) 0.11
Procedure
Stents used: 0 - no. (%) 60 (5.2) 32 (6.2) 5 (3.1) 9 (5.4)
Stents used: 1 - no. (%) 751 (64.7) 269 (52.1) 57 (35.8) 51 (30.7)
Stents used: 2-3 - no. (%) 316 (27) 179 (34.7) 75 (47) 74 (45)
Stents used: >3 - no. (%) 34 (2.9) 36 (7.0) 22 (14) 32 (19) <0.0001
IQR Interquartile range, CCS Canadian Cardiovascular Society classification of angina pectoris. P values reflects chi-square statistics comparing the five groups
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significant and there were relatively few patients avail-
able for follow up in each of the other three groups at
this time (Fig. 2). The results were unchanged in multi-
variable analyses that included age and gender (Fig. 3).
The corresponding curves for the combined endpoint of
all-cause mortality and new onset heart failure showed
early separation of the curves but with an unclear pat-
tern. The group with post-PCI cTnT >70–200 ng/L was
without significant separation from the group with cTnT
≤14 ng/L. However, the groups with cTnT >14–70 ng/L
and above 200 ng/L did show separation of the curves
throughout the follow-up period (Fig. 4).
In stratified analysis the hazard rates for time until
death after post-PCI, peak cTnT was compared to the
strata with cTnT < URL. There were no statistically sig-
nificant differences regarding the primary endpoint of
all-cause mortality with hazard ratios (HR) respectively
in order of rising cTnT 1.62 (95 % confidence interval
(CI) 0.97–1.63 p = 0.07), 0.99 (95 % CI 0.76–1.30 p =
0.96) and 1.21 (95 % CI 0.92–1.60 p = 0.17).
There were a few statistically significant differences
when analyzing the combined endpoint of all-cause mor-
tality or new onset heart failure the HRs in stratified
analysis. The HR were respectively in order of rising
cTnT 1.28 (95 % CI 1.04–1.58 p = 0.02), 1.18 (95 % CI
0.94–1.48 p = 0.16) and 1.31 (95 % CI 1.03–1.67 p =
0.03). There was trend towards higher cTnT being
associated with higher risk. However, the group with
cTnT 70–200 ng/L was not statistically significant. To
further examine this, we additionally re-grouped values
into three groups by peak post cTnT and compared the
group with cTnT ≤14 ng/L to a group with cTnT >14–
70 ng/L (HR 1.1 (95 % CI 0.97–1.34 p = 0.11) and a
group with cTnT above 70 ng/L (HR 0.92 (95 % CI
0.78–1.09 p = 0.35). When grouped in three groups there
was no statistically significant differences.
There was no significant difference regarding all-cause
mortality when analyzed in four groups after peak post-
PCI CK-MBmass: <URL, between URL and 5 x URL (HR
1.96 (95 % CI 0.76–5.05 p = 0.16), between 5 and 15 x
URL (HR 1.16 (95 % CI 0.55–2.44 p = 0.69) and above 15
x URL (HR 0.87 (95 % CI 0.55–1.37 p = 0.55) (Fig. 5). The
results were unchanged in multivariable analyses that in-
cluded age and gender. There was no clear pattern regard-
ing the combined endpoint of all-cause mortality and new
onset heart failure when analyzed in four groups after
peak post-PCI CK-MBmass.: <URL, between URL and 5 x
URL (HR 1.97 (95 % CI 1.19–3.27 p = 0.0088), between 5
and 15 x URL (HR 1.15 (95 % CI 0.77–1.72 p = 0.50) and
above 15 x URL (HR 0.88 (95 % CI 0.68–1.15 p = 0.36).
The results were unchanged in multivariable analyses that
included age and gender.
Discussion
The aim of this study was to examine the incidence of car-
diac biomarker elevation according to the definition of
peri-procedural MI given by the European Society of
Cardiology-guidelines “Third Universal definition of MI”
type 4a myocardial infarction, and to determine whether
this carries independent prognostic value. The elevation of
cTnT could be linked directly to the procedure, since only
patients with normal baseline cTnT were included. Our
population had an even distribution of patient characteris-
tics with few differences and the differences in kidney func-
tion and previous MI do not seem clinically relevant since
they do not have a clear pattern, and the differences are
small. The only statistically significant and clinically mean-
ingful differences between the groups were age and number
of stents used. The incidence in our population using the
cTnT cut off >5 x URL (cTnT >70 ng/L) was 15.2 %,
For the primary endpoint of all-cause mortality, we
did not find that any interval of troponin was associated
with an increased all-cause mortality. However, we did
find a possible association between elevation of cTnT
and the combined endpoint of new onset heart failure
and all-cause mortality with the groups with cTnT >14–
70 ng/L and >200 ng/L since these groups had border-
line statistically significantly higher risk compared to the
group with cTnT ≤14 ng/L. Regarding the combined
endpoint of new onset heart failure and all-cause mortal-
ity and CKMB there was also a seemingly isolated risk
Fig. 2 Kaplan-Meier curve of all-cause mortality by peak concentration
of troponin T in ng/L. Each colored line representing one group
according to peak concentration of troponin T. Duration of follow up in
years from index procedure. Below the Kaplan-Meier curve is the
number of patients still available for follow-up in each group
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associated with values between URL and 5x URL, but
not with higher levels of CK-MB.
When using CK-MBmass the fraction of patients with
elevated cardiac biomarkers was much lower than for
cTnT (15.2 % versus 4.1 % respectively). The reason for
this is probably, that cTnT is a more sensitive biomarker
than CKMB mass. In contrast to some previous studies,
we found that CK-MBmass was not an independent
marker for prognosis [3, 4]. However, in our study we used
CKMBmass, which is a more sensitive biomarker than
CKMBcatalytic activity, and the >5 URL of CKMBmass
corresponds to approximately an increase in CKMBcataly-
tic activity of 1–2 times URL; which in these studies did
not show any prognostic information.
The fraction of elevated cardiac biomarkers found in
our study is slightly higher than previously reported in
meta-analysis by Testa et al. [12] They showed a detect-
able elevation of cTn after scheduled PCI in 28.7 % of
7578 patients (compared to 37.7 % in our study), and in
14.5 % of the patients cTn exceeded 3 x 99th percentile
URL (the previously used cut-off value) [13]. The data
used by Testa et al. was of a more heterogeneous popu-
lation with 7 studies including unstable angina and
different assays including both cTnT and cTnI. Further-
more, different cut-off values for cTnT were allowed in-
cluding 100 ng/L which even with 3 x URL (=300 ng/L)
is far above the presently supported 70 ng/L. It seems
Fig. 3 Forest Plot displaying Multivariate Cox Regression analysis for all-cause mortality. cTnT = peak post procedural concentration of troponin T
in ng/L. Age signifies risk pr. year and sex risk associated with being male
Fig. 4 Kaplan-Meier curve of the combined endpoint of all-cause
mortality or new onset heart failure by peak concentration of
troponin T in ng/L. Each colored line representing one group
according to peak concentration of troponin T. Duration of
follow-up in years from index procedure. Below the Kaplan-Meier
curve is shown the number of patients still available for follow-up
in each group
Fig. 5 Kaplan-Meier curve of all-cause mortality by peak post procedural
concentration of CK-MBmass. The values for women in μg/L are shown
in the figure with values for men in parentheses. Duration of follow-up
in years from index procedure. Below the Kaplan-Meier curve is shown
the number of patients still available for follow-up in each group
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likely, that these differences explain the lower occur-
rence of cTn above URL. In their meta-analysis there
was a significant risk associated with elevation of cTn
above 3 x URL, but this conclusion seems uncertain in
our study of a more homogenous patient group. We
found no association between biomarker elevation and
all-cause mortality but a possible association between
the combined endpoint of all-cause mortality and new
onset heart failure. There is little doubt when examining
the combined data that the presently used hsTnT is in-
deed highly sensitive and the present cut-off makes cTn
elevation corresponding to peri-procedural MI a very
common occurrence following elective PCI.
Peri-procedural MI can be difficult to rule out - as the
symptoms, electrocardiographic changes, angiography
and other imaging modalities can be uncertain due to
older ischemic injuries and discomfort associated with
the procedure itself. A study showed that on angiog-
raphy only approximately 60 % of peri-procedural MI
could be explained [14]. Clinicians must therefore rely
considerably on cardiac biomarkers. However, this is not
without difficulties, as a definite cut-off value for prog-
nostic significance has not been established for the
present sensitive cardiac biomarkers, and the nature of
the association between elevated biomarkers after PCI
and prognosis is still under discussion [2, 3, 15–21]. The
question is whether increased all-cause mortality is
caused by acute PCI-related myocardial necrosis or
whether the elevations of biomarkers is due to diffuse
cTn release functioning as a general indicator of in-
creased risk. In a meta-analysis the relationship between
elevated cTnI or cTnT above URL after elective PCI
and all-cause mortality was shown to be statistically sig-
nificant with increased long-term (3–67 months) all-
cause mortality of 5.8 % compared to 4.4 % in the group
without elevated cTn [22]. These studies were performed
before the Third Universal definition of peri-procedural
MI – type 4a – was defined. Furthermore, cut-offs of
TnI or TnT were not given in the meta-analysis.
The issue is further opaqued by the diversity of PCI
related causes of increased cTn such as re-perfusion of
an already injured area, distal embolization, coronary
dissection, coronary spasm, occlusion of a sidebranch or
even major coronary artery, microvascular plugging, dis-
ruption of collateral flow, slow flow or no-reflow [23].
Some of these specific causes might be prognostically
significant, but this might be overlooked, when all causes
are examined as one general group with elevated bio-
markers. In non-elective PCI the post-PCI elevation
might be caused by a pre-PCI injury and an already ris-
ing baseline value as seen in acute coronary syndrome
[15, 20, 21, 24]. It has been hypothesized that there are
multiple risk factors. Marked elevations of biomarkers
after elective PCI could be associated with large
infarction area, which is known to be associated to in-
creased risk of death by heart failure and malignant ar-
rhythmias with worsening prognosis [25, 26]. On the
contrary, smaller elevations might not represent an actu-
ally MI, but be an indicator of extensive coronary athero-
sclerosis and high procedural complexity, this is however,
also known to be related to poorer long term outcome
[18, 22, 27]. In previous studies, prognostic significance
was demonstrated for post-PCI elevation of CK-MB [23,
28, 29]. However, cTn is now accepted as a more sensitive
marker of myocyte necrosis than CK-MB [1, 18, 24] and
therefore, it can be assumed that peri-procedural MI diag-
nosed on the basis of CK-MB had relatively larger prob-
ability of representing a severe MI than if based on cTn.
However, in our study, there is no indication that CK-
MBmass is a significant prognostic indicator, probably due
to absolute low concentrations at >15 times URL in com-
parison to older studies, or superior to TnT.
To the best of our knowledge, the numerous studies
previously describing elevated biomarkers after PCI all
have considerably shorter follow up. Assuming that the
prognostic significance of peri-procedural MI is due to
myocardial scarring followed by development of heart
failure and/or malignant arrhythmias, it seems reason-
able that the difference in prognosis should progress
over time. The shorter follow up of previous studies
might lead to underestimation of risk, but based on our
data this is a not the case.
Limitations
Our study is a historic follow-up and is not able to report
on any causality between peri-procedural MI and adverse
events. Furthermore no data regarding symptoms, electro-
cardiographic changes or imaging is available to the study
group so we cannot conclude whether the patients found
with elevated cTnT ≥ 5 x URL also fulfilled the other de-
fined criteria in the Third Universal Definition of Myocar-
dial Infarction which includes patient reported symptoms,
electrocardiographic or imaging suggestive of myocardial
ischemia [1]. Due to the design of the study, it was neces-
sary to use a surrogate marker for new-onset heart failure.
Using hospitalization for heart failure as endpoint, was
considered too insensitive, as a diagnosis of heart failure is
known to be an unreliable marker with a sensitivity of
about 25 % [30]. We expect most cases of overt heart fail-
ure to receive furosemide in Denmark, but acknowledge
that some patients with obstructive lung disease and kid-
ney disease may also receive this treatment, but it was
deemed the best marker available when combined with
hospital admittance due to heart failure.
It should be noted, that our data is from a strictly stable
population and not “non-emergent” as used in many pre-
vious studies. Emergent is typically defined as procedures
that have to be performed within hours of symptom onset.
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This group can include both recent non-ST-elevation
myocardial infarction (NSTEMI) and unstable angina.
NSTEMI can cloud the issue due to a rising baseline of
cTn and also represents a higher risk of procedural com-
plications. Therefore, the conclusions from this study
should only be applied with great care to other than truly
stable patients.
Conclusion
The incidence of elevated biomarkers after elective
PCI in patients with stable angina pectoris using the
cut-off set by the Third Universal Definition of Myo-
cardial Infarction (>5 x URL) was 15.2 % using cTnT
and 4.1 % using CK-MBmass. The independent prog-
nostic value of any cutoff for both cardiac bio-
markers does not seem certain in neither short-term
nor in long-term follow-up.
Our data suggest that routine measurement of cardiac
biomarkers after elective PCI is not relevant unless pro-
cedural complications occur. We acknowledge that clin-
ically driven measurement and observation after PCI in
patients with stable angina pectoris is still relevant.
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